Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium Patent Expiration

Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium was first introduced by Rb Health Us Llc in its drug Mucinex 12Hr Cold & Fever Multi-Symptom on Dec 22, 2025.


Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium Patents

Given below is the list of patents protecting Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Mucinex 12hr Cold & Fever Multi-symptom US11278506 Pharmaceutical Formulation Oct 11, 2036 Rb Hlth
Mucinex 12hr Cold & Fever Multi-symptom US12257218 Pharmaceutical Formulation Oct 11, 2036 Rb Hlth
Mucinex 12hr Cold & Fever Multi-symptom US12370189 Pharmaceutical Formulation Oct 11, 2036 Rb Hlth



Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium Generic API Manufacturers

Given below is the list of companies who have filed for Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium generic, along with the locations of their manufacturing plants worldwide.